Loading page...
Loading page...
This round is closed. Synced from the EU Funding & Tenders Portal on 9 November 2026.
Based on projects the EU funded on the same subject in this programme.
IMPROVE PRETERMIMPROVing lifElong health and development for children and adults born very PRETERM – observational studies to enhance randomised trials for comparative effectiveness research
HORIZON-HLTH-2024-DISEASE-03-08-two-stage · 2025 · Official record ↗
ACTSAccelerating Tobacco Cessation within Healthcare Systems of European LMICs: A Multi-Country Implementation-Effectiveness Trial
HORIZON-HLTH-2025-01-DISEASE-06 · 2026 · Official record ↗
THERESA PCPPre-Comercial Procurement of innovative and sustainable solutions to Treat HEalthcaRE System wAstewater
HORIZON-HLTH-2024-CARE-14-01 · 2025 · Official record ↗
EU2025DK - HEALTHEU2025DK - HEALTH
HORIZON-HLTH-2024-PDEN-18-01-IBA · 2025 · Official record ↗
SP-EUSocial Prescribing to promote and improve access to health and care services for people in vulnerable situations in Europe
HORIZON-HLTH-2024-CARE-04-04-two-stage · 2025 · Official record ↗
REHEALReverse Healthcare Supply Chains for Circular Economy
HORIZON-HLTH-2024-CARE-14-01 · 2025 · Official record ↗
YOUTHreachBridging Gaps in Mental Health Support: A Comprehensive European Strategy
HORIZON-HLTH-2024-DISEASE-03-08-two-stage · 2025 · Official record ↗
INSPIREINtegrated Short-term PallIative REhabilitation to improve quality of life and equitable care access in incurable cancer
HORIZON-HLTH-2021-DISEASE-04-01 · 2022 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
Low-value care, as defined in the footnote, can have widespread negative consequences for patients, caregivers, healthcare professionals, the health and care system, and the broader environment. A 2017 OECD report[2] estimated that “wasteful healthcare spending is common” and that “up to one-fifth of healthcare spending could be redirected towards better uses”. Low-value care represents a significant challenge, contributing to waste, costs, misuse of resources, and inefficiencies. Addressing low-value care can free up and allow reallocation of valuable healthcare resources to other areas of need, thereby maximising health outcomes, improving health and care systems resilience, and reducing their environmental impact. In this context, a recent report[3] by the Expert Group on Health Systems Performance Assessment (HSPA)[4] establishes the methodological basis and metrics to identify, measure and reduce low-value care.
Research activities under this topic should adopt a patient-centred approach that considers the needs and preferences of patients and citizens. They should promote socially acceptable solutions, taking into account relevant ethical, social and legal aspects and foster dialogue and collaboration between policymakers, healthcare providers, healthcare professionals, and patients/citizens. Proposals should engage citizens and civil society organisations in the development of their actions to ensure acceptability of solutions. By doing so the projects will contribute to better use of healthcare resources -including time and personnel- in ways that significantly improve patient outcomes and alleviate the increasing burden on healthcare professionals and health systems. Implementation research and multidisciplinary approaches should be considered to foster adoption and ensure effective interventions and long-term sustainability.
Proposed activities may[5] include clinical studies[6] to provide evidence on the value of any interventions or processes and, therefore, facilitate justified removal of any type of low value care. Proposed activities may also include data models, digital and artificial intelligence-based analysis, models and/or tools to identify and/or address low-value care. Proposed activities may examine the design and impact of healthcare payment systems, that could unintentionally incentivise low-value care and evaluate alternative financing models that better align incentives with patient outcomes and high-value care. Proposed activities may also facilitate or implement collaboration among registries (disease registries such as cancer registries, primary healthcare visits registries, prescription and drug purchase registries, reimbursement and medical devices registries, screening databases, socio-economic and census databases, etc.) across regions or countries, to enable or improve the assessment and comparison of different levels of care and their value to patients. Additionally, activities that facilitate learning and best practice transfers between countries or regions may also be considered as element of the proposal (for instance, to leverage best practice-sharing initiatives from international platforms such as the Knowledge Hub of the co-funded European Partnership on Transforming Health and Care Systems[7] or any other relevant European or global initiatives). Additionally, proposals may include or support international comparisons of low-value care practices and strategies for their reduction across countries, if and where deemed valuable.
Research actions should address all the following objectives:
Proposals should consider how gender norms and roles influence utilisation patterns, ensuring that strategies to reduce low-value care do not inadvertently exacerbate existing gender and social inequalities in healthcare access and outcomes. In addition, attention should be paid to intersectional factors that may further affect healthcare access and outcomes. If handling data and indicators, sex- and gender-disaggregated data should be collected and analysed, incorporating intersectional factors where feasible.
Proposals should consider the work and output of any EU level initiatives (e.g. the Expert Group on Health Systems Performance Assessment, the co-funded European Partnership on Transforming Health and Care Systems, relevant projects or Joint Actions funded under the EU4Health Programme (2021-2027)[8] and under EU Research & Innovation Framework Programmes, etc.) or other international initiatives (e.g. the 2017 OECD report mentioned above) in this area.
Applicants envisaging[5] to include clinical studies[6] should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.
[1] Definition of low-value care from the Report by the Expert Group on Health Systems Performance Assessment: “From a health system perspective, low-value care encompasses overuse, misuse and underuse of healthcare services (for example, prevention, diagnostics, treatment, medication). Overuse and/or misuse comprise the delivery of harmful, ineffective, inappropriate, or not cost-effective healthcare services. Underuse refers to healthcare services not provided or used despite being necessary. Low-value care can lead to negative consequences for patients, their caregivers, the healthcare workforce, the health system as a whole and the wider environment.”
[2] OECD (2017), Tackling Wasteful Spending on Health, OECD Publishing, Paris. http://dx.doi.org/10.1787/9789264266414-en
[3] Report by the Expert Group on Health Systems Performance Assessment: “Identifying, Measuring And Reducing Low-Value Care In The Context Of Health System Performance Assessment”. https://health.ec.europa.eu/publications/identifying-measuring-and-reducing-low-value-care-context-health-system-performance-assessment_en
[4] https://health.ec.europa.eu/health-systems-performance-assessment_en
[5] Some proposals may not need to conduct clinical studies to achieve the objectives.
[6] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
[7] https://cordis.europa.eu/project/id/101095654, https://www.thcspartnership.eu
[8] https://commission.europa.eu/funding-tenders/find-funding/eu-funding-programmes/eu4health_en
[9] Some proposals may not need to conduct clinical studies to achieve the objectives.
[10] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Subject to restrictions for the protection of European communication networks.
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
HE Programme Guide
Model Grant Agreement (MGA)
HE MGA
Call-specific instructions 
Information on clinical studies (HE)
Additional documents
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 13 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
The protection of European communication networks has been identified as an important security interest of the Union and its Member States. For further details, you are advised to refer to the introduction of the destination under which this topic falls (as found in the Health Cluster work programme part for 2026-27).
Read it on the EU portal ↗Answered 7 Oct 2026
No, this topic is not using the Lump Sum funding model.
Read it on the EU portal ↗Answered 2 Nov 2026
Please note that the definition of clinical studies, together with additional useful information can be found in the introduction of Health Cluster Work Programme part for 2026-2027.
Additionally, we would like to bring to your attention the fact that the World Health Organization (WHO) has published a “Guidance for best practices for clinical trials”. You are not required not follow this guidance, however we encourage you to do so.
Finally, we would also like to encourage you to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings.
Read it on the EU portal ↗Answered 28 Jun 2026
Yes, proposals focusing on specific disease areas can be within scope. In fact, the topic encourages the identification of instances of low-value care practices in specific healthcare contexts as well as developing and/or piloting innovative strategies to reduce LVC in specific settings.
Read it on the EU portal ↗Answered 13 Apr 2026
One of the activities expected in this topic is developing and/or piloting strategies that “demonstrate scalability and transferability across diverse health and care systems in Europe”. Given this, in most cases, a certain level of involvement or collaboration from health authorities, insurers/payers, healthcare providers, healthcare professionals, or any other actors involved in the management, financing and/or provision of healthcare services will most probably be of interest.
Read it on the EU portal ↗Answered 24 Mar 2026
It is not imperative for proposals to implement interventions to reduce low-value care in the clinical setting. However, developing and/or piloting low-value care reduction strategies in specific settings is highly encouraged by this topic.
Read it on the EU portal ↗Answered 24 Mar 2026
Identification and reduction of administrative and/or organisational driven low-value care practices could be within the scope of this topic.
According to the definition of low-value care from the European Commission's Expert Group report on Health Systems Performance Assessment (HSPA), Low Value Care encompasses the overuse, misuse, and underuse of healthcare services (prevention, diagnostics, treatment, medication) that provide little or no health benefit, or where potential harm exceeds benefits.
Therefore, identifying and reducing administrative and/or organisational activities could be relevant in instances in which these activities could be driving the overuse, misuse, or underuse of specific healthcare services.
Read it on the EU portal ↗Answered 25 Mar 2026
Clinical studies are a possibility if needed and pertinent, but not a mandatory activity.
Read it on the EU portal ↗Answered 24 Mar 2026
Yes, synergies with other nationally funded projects are allowed and pertinent as long as there is no double funding.
Read it on the EU portal ↗Answered 24 Mar 2026
Please refer to the report by the European Commission's Expert Group on Health Systems Performance Assessment (HSPA)[1] for this question. In any case it is not required to address all three aspects (e.g. overuse, underuse and misuse) in the same proposal.
Read it on the EU portal ↗Answered 24 Mar 2026
For the purpose of this topic, by “pilot strategies” we mean initial trials or implementations of new health strategies or interventions on a smaller scale in real-world settings to test their viability, effectiveness, potential impact, etc. before wider adoption.
Unlike clinical studies, these pilot strategies may not necessarily focus on evaluating medical or clinical interventions under strictly controlled conditions. Instead, they may involve testing innovative approaches in real-world health and care settings to assess practical aspects such as feasibility, adaptability or potential scale-up integration into existing systems.
Read it on the EU portal ↗Answered 24 Mar 2026
Although the use of real-world data is not explicitly encouraged in the topic text but it is possible. If relevant, such data may be used and their added value should be described in the proposal.
Read it on the EU portal ↗Answered 24 Mar 2026
The Health Cluster Work Programme part for 2026-2027 includes a “right to object” condition for nearly all topics, giving the granting authority the right to object to a transfer of ownership or to the exclusive licensing of results, up to 4 years after the end of the action.
For applicants and beneficiaries, little is expected to change, as in previous years this condition had been part of the General Annexes, having legal force across all parts of Horizon Europe (including the Health Cluster topics). In practise, the granting authority may invoke the “right to object” under specific conditions, which so far has happened in very rare occasions over the many years of Horizon Europe.
More details below from Annex 5 of the General Model Grant Agreement:
Where the call conditions in Horizon Europe actions provide for the right to object to transfers or licensing, the granting authority may — up to four years after the end of the action — object to a transfer of ownership or the exclusive licensing of results, if:
the beneficiaries which generated the results have received funding under the grant
it is to a legal entity established in a non-EU country not associated with Horizon Europe, and
the granting authority considers that the transfer or licence is not in line with EU interests.
Beneficiaries that intend to transfer ownership or grant an exclusive licence must formally notify the granting authority before the intended transfer or licensing takes place and:
identify the specific results concerned
describe in detail the new owner or licensee and the planned or potential exploitation of the results, and
include a reasoned assessment of the likely impact of the transfer or licence on EU interests, in particular regarding competitiveness as well as consistency with ethical principles and security considerations.
The granting authority may request additional information.
If the granting authority decides to object to a transfer or exclusive licence, it must formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information it has requested).
No transfer or licensing may take place in the following cases:
pending the granting authority decision, within the period set out above
if the granting authority objects
until the conditions are complied with, if the granting authority objection comes with conditions.
A beneficiary may formally notify a request to waive the right to object regarding intended transfers or grants to a specifically identified third party, if measures safeguarding EU interests are in place. If the granting authority agrees, it will formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information requested).
Read it on the EU portal ↗Answered 28 Jun 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.